Company Products Research Collaborators Regulatory Investor Relations Contact Us  


Nuovo Biologics meets with FDA Center for Veterinary Medicine
January 24, 2011

Rockville, MD - The pre-NADA (New Animal Drug Application) Conference was convened with the FDA Center for Veterinary Medicine staff on January 24th. The meeting focused on our three phased clinical research strategy to complete the proposed New Animal Drug Applications. Discussions centered on Phase One studies including the proposed pilot malignant melanoma study to meet the Conditional New Animal Drug Application regulatory requirements, as well as product manufacturing requirements, and requisite safety studies. Nuovo Biologics, in conjunction with Auburn University, School of Veterinary Medicine, will initiate clinical trials this spring.

January 15, 2011

Orlando, Florida - The Members of Nuovo Biologics, LLC assembled for their annual Members meeting and to elect their Board of Directors. The Directors include company CEO Dr. Jay E.Yourist, company COO/CFO Gregory Carney, founding member Dr. Kent Miller, and investor Donald Denkhaus, who was selected as Chairman. Jeffery Fisher, of Pittsburgh, PA, representing a group of angel investors, was also selected to serve on the board.

Both Mr. Denkhaus and Mr. Fisher bring to the company a wealth of experience in the pharmaceutical and corporate world. After his election as Chairman, Mr. Denkhaus said; "I am delighted to accept this opportunity to help guide this company. We have an impressive array of talent, experience, and willingness to undertake the task ahead of us."

Nuovo Biologics, LLC is a new animal health product research and development company dedicated to innovative, safe and efficacious products such as drugs, biological and supplements that best support and maximize animal health. Nuovo Biologics, LLC provides, through its network, information sharing, training and education for clinical research and new product development among all animal industry stakeholders.

October 06, 2010

Nuovo Biologics was assigned an Investigational New Animal Drug (INAD) number for PANAVIRA™ for its proposed use as a broad spectrum antiviral drug in non-consumable animals (dogs, cats, horses and birds). For more information please visit Our Products.

October 05, 2010

The United States Patent Office issued Patent #USSN 7,807,635 for PANAVIRA™ mechanisms of action and related disease indications.

August 26, 2010

The FDA Center for Veterinary Medicine (CVM) under the Animal Drug User Fee Act (ADUFA), granted Nuovo Biologics an extension of the Waiver Sponsor Fees for FY 2011.( See March 9, 2010).


First - Previous - Next - Last Showing 31 to 35 of 37